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Abstract
Background: Hepatitis C infection (HCV) and hepatocellular carcinoma (HCC), the two main causes of
liver transplantation (LT), have reduced survival post-LT. The impact of HCV, HCC and their coexistence
on post-LT survival were assessed.
Methodology: All 601 LT patients from 1992 to 2011 were reviewed. Those deceased within 30 days
(n = 69) and re-transplants (n = 49) were excluded. Recipients were divided into four groups: (a)
HCC-/HCV-(n = 252) (b) HCC+/HCV- (n = 58), (c) HCC-/HCV+ (n = 106) and (d) HCC+/HCV+ (n = 67).
Demographics, the donor risk index (DRI), Model for End-Stage Liver Disease (MELD) score, survival,
complications and tumour characteristics were collected. Statistical analysis included ANOVA, chi-square,
Fisher's exact tests and Cox and Kaplan–Meier for overall survival.
Results: Groups were comparable with regards to baseline characteristics, but HCC patients were older.
After adjusting for age, MELD, gender and the donor risk index (DRI), survival was lower in the HCC+/
HCV+ group (59.5% at 5 yrs) and the hazard ratio (HR) was 1.90 [95% confidence interval (CI),1.24–2.95,
P = 0.003] and 1.45 (95% CI, 0.99–2.12, P = 0.054) for HCC-/HCV+. HCC survival was similar to controls
(HR 1.18, 95% CI, 0.71–1.93, P = 0.508). HCC+/HCV- patients exceeded the Milan criteria (50% versus
31%, P < 0.04) and had more micro-vascular invasion (37.5% versus 20.6%, P = 0.042). HCC+/HCV+
versus HCC+/HCV- survival remained lower (HR 1.94, 95% CI, 1.06–3.81, P = 0.041) after correcting for
tumour characteristics and treatment.
Conclusion: HCV patients had lower survival post-LT. HCC alone had no impact on survival. Patient
survival decreased in the HCC+/HCV+ group and this appears to be as a consequence of HCV
recurrence.
Received 10 August 2012; accepted 28 November 2012
Correspondence
Jean I. Tchervenkov, Royal Victoria Hospital, 687 Pine Avenue West, Room S10.26, Montreal, Quebec,
Canada, H3A 1A1. Tel: +1 514 934 1934 ext. 34042. Fax: +1 514 843 1503. E-mail: jean.tchervenkov@
muhc.mcgill.ca
Introduction
Hepatitis C virus (HCV) is one of the leading causes of end-stage
liver disease (ESLD), as 3% of the world population is chronically
infected.1–4 Liver transplantation (LT) remains the only curative
treatment.5 While long-term survival after orthotopic LT (OLT)
has greatly improved over the past decades, the 10-year survival
post-LT for HCV is reported to be 60%,6,7 remaining inferior to
many other causes of ESLD. The 5-year cumulative risk of devel-
oping hepatocellular carcinoma (HCC) for patients with ESLD is
up to 30%.8 HCV infection increases the risk of HCC by 14- to
22-fold when compared with HCV-negative patients.9
According to the International Agency for Research on Cancer,
HCC is currently the fifth most common cancer worldwide.4 The
pivotal work by Mazaferro et al. successfully identified a group of
patients with a post-LT survival similar to that of non-cancer
patients.10 However 15 years later, the literature still fails to reach
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a consensus on the impact of HCV on survival post-LT in patients
with HCC. Some previous studies have demonstrated the inde-
pendent negative impact of HCV on survival in patients trans-
planted with HCC11–15 whereas others have not.16–18 These studies
are however limited at 5-year survival.
We believe that the effect of HCV on survival in patients trans-
planted for HCC becomes significantly detrimental beyond 5
years post-LT. The goal of this study was to assess the long-term
impact of the coexistence of HCV and HCC on recipient and graft
survival post-LT. The secondary outcomes were the cause of death
(COD) for all our patients, the 90-day complications and the
length of intensive care unit (ICU) stay and admission.
Methodology
Patient selection
A retrospective study of this prospectively collected transplant
database was conducted. All LTs performed at the McGill Univer-
sity Health Center from January 1st 1992 to December 1st 2010
were reviewed (n = 601). Given that the study’s primary outcome
was long-term survival, patients were excluded if they required
re-transplantation or died within 30 days (n = 69). Only the
primary transplant was analysed in this study, thus second or third
LTs for the same patient were excluded (n = 49). The remaining
483 recipients were divided into four groups (Fig. 1): patients
transplanted for causes other than HCV and HCC (HCC-/HCV-)
(n = 252), those transplanted for HCC alone and other causes of
liver cirrhosis (HCC+/HCV-) (n = 58), patients with HCV cirrho-
sis alone (HCC+/HCV-) (n = 106) and those with both HCV
cirrhosis and HCC (HCC+/HCV+) (n = 67). This grouping
enables us to assess the independent impact of HCC and HCV on
outcome, as well as that of their conjoint presentation.
Baseline characteristics
Recipient demographics, the natural Model for End-Stage Liver
Disease (MELD) score and the donor risk index (DRI) were
retrieved. The DRI score is based on donor age, race, height, COD,
donation after cardiac death, use of a split liver, type of allocation
and cold-ischemia time.19 Adherence to Milan criteria, as deter-
mined at the time of listing using pre-operative radiological
imaging [computed tomography (CT) scan, ultrasound (US) and
magnetic resonance imaging], was also collected. Tumour charac-
teristics were established using explant histopathology: the grade
of the tumour based on (2 and less versus more than 2), the
number of tumours (3 and less versus more than 3), the total
tumour size (less than 5 cm versus 5 cm and larger) and the pres-
ence of micro-vascular invasion. In this institution, HCC bridging
treatments are reserved for patients with lesions with demon-
strated growth as demonstrated by radiological modalities or
lesions greater than 3 cm, while awaiting transplantation.
Bridging therapy consisted mainly of trans-arterial chemo-
embolization (TACE). In addition to TACE, some patients
received percutaneous ethanol injections, systemic chemotherapy
and intra-arterial chemotherapy. No patients underwent resection
for downstaging. HCV diagnosis was performed through serology
and confirmed by serum HCV rNA as of 1996. Patients with
advanced cirrhosis requiring LT were not treated prior to
transplantation.
In this cohort, eligibility for LT was determined by the transplant
selection committee based on underlying cause of ESLD, HCC size
and characteristics. Absolute contraindications were radiological
evidence of HCC macrovascular invasion or extra-hepatic disease.
LT listings were performed on the base of patient status (whether
the patient was at home, hospitalized, in the ICU or on life-
support) as per Quebec transplant guidelines at the time of listing
until 2009 and based on the MELD score with adjustment for HCC
patients thereafter. Selection based on Milan criteria was only
formally introduced in this cohort in 2009. The immunosuppres-
sion in most patients consisted of induction with Thymoglobulin®
(Pfizer, Saint-Laurent, Quebec. Canada), a calcineurin inhibitior
Tacrolimus® (Astellas, Markham, Ontario, Canada) or Neoral®
(Novartis, Dorval Montreal, Quebec, Canada), azathyropine
(GlaxoSmithKline, Mississauga, Ontario, Canada) until 1997 and
mycophenolate mofetil (Roche, Mississauga, Ontario, Canada)
after 2007. More than 80% of the patients had prednisone discon-
tinued after the first year post-OLT. Post-LT HCV treatment was
initiated in patients with evidence of HCV recurrence on a liver
biopsy performed based on clinical grounds of elevated or rising
liver enzymes. The treatment consisted of alpha interferon from
1995 to 2000 and as of 2000 this institution started using pegalated
alpha interferon and ribavirin.
Follow-up
The primary outcome was survival at last follow-up contact
(ranging from 18 months to 20 years). Patients that were not
deceased at the end of the study were censored at that time. Graft
survival was also considered in the same fashion. Secondary out-
comes were complications within 90 days of transplantation clas-















30 days (n = 69)
Second grafts
(n = 49)
Figure 1 Patient selection flowchart. OLT, orthotopic liver transplan-
tation; MUHC, McGill University Health Center, HCC, hepatocellular
carcinoma; HCV, hepatitis C infection
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infectious and wound complications. The length of ICU stay and
admission were also examined. HCV recurrence was ascertained
through serology and histologically confirmed after liver biopsy
for cause of elevation of liver transaminases.
HCC patients were followed by US and alpha-feto protein levels
twice a year post-OLT. If an abnormality was detected, HCC recur-
rence was assessed by CT scan, PET scan, biopsy or autopsy. HCV
genotyping was not routinely available at this centre until 1999
and was thus not included in this study. A 98.2% complete
follow-up was achieved with losses to follow-up owing to LT
recipients leaving the province. A great majority of deaths
occurred in this hospital centre and where the primary cause of
death was recorded in the database as indicated on the death
certificate and the physician notes or from autopsy reports. In the
minority of cases where the patients died in another hospital or at
home, communication with the family of the recipient or primary
physician confirmed the cause of death and was prospectively
collected in this database.
Statistical analysis
Statistical analysis of donor and recipient baseline characteristics,
length of admission and ICU stay was performed using anova.
For tumour characteristics, the chi-square or Fisher’s exact tests
were used.
Survival at 5 and 10 years for each group was estimated using
the Kaplan–Meier curve and a log rank test was used to assess
whether the observed differences were statistically significant.
After verifying compliance with the proportionality assumption, a
Cox multivariate regression was performed to assess independent
predictors of outcome. The selection of variables included in the
model was predetermined based on our literature review. It was
also assessed whether there was a potential interaction effect
between HCC and HCV. A Cox multivariate sub-analysis was
performed to assess an impendent predictor of survival in the
HCC+ patients.
When comparing different causes of death across the four




Recipients were comparable for natural MELD and DRI between
the four groups (Table 1). Recipients in the two HCC+ groups
were older (61.2 in HCV- and 58.4 in HCV+) when compared
with the cancer-free groups (53.9 and 55.3, P < 0.000) and were
predominantly male (P = 0.032).
Tumour characteristics
The non-HCV group (HCC+/HCV-) had a significantly greater
rate of microvascular invasion than the HCV+ group (HCC+/
HCV+) (37.5% versus 20.6%, P = 0.042). The HCC+/HCV- group
tended to exceed Milan criteria when compared with the infected
group (50% versus 26%, P = 0.027). The two HCC+ groups were
otherwise comparable for the number of lesions, the total tumour
size and pre-LT bridging treatments (Table 2).
Survival analysis
The Kaplan–Meier survival curves are presented in Fig. 2. The
survival estimates (Table 3) were similar among the first three
Table 1 Basic characteristics presented in terms of means and standard deviation (SD), the P-value results from the ANOVA test performed














Age 53.9  11.8 61.2  6.2 55.3  9.2 58.4  8.2 <0.000*
Male 63.4% 86.2% 65.1% 76.1% 0.032*
MELD score 22.7  9.6 20.7  2.2 21.5  8.4 20.6  3.4 0.128
DRI 1.55  0.34 1.57  0.35 1.55  0.35 1.62  0.38 0.469
ICU stay (days) 8.1  9.4 5.6  6.6 7.2  8.7 6.5  7.3 0.183
Length of admission (days) 52.2  50.4 49.7  67.2 50.9  47.1 44.5  46.9 0.758
Other causes of cirrhosis Total
HBV 11.9% 42.1% 4.72% 2.9% 12.63%
ALD 31.6% 29.8% 22.6% 11.9% 26.7%
NASH 11.3% 10.5% 0.0% 0.0% 7.9%
PBC 10.7% 1.8% 0.0% 0.0% 5.8%
PSC 9.5% 0.0% 0.0% 1.5% 5.2%
Cryptogenic 7.9% 7.0% 0.0% 0.0% 5.0%
Toxic 2.8% 0.0% 0.0% 0.0% 1.5%
HCC, hepatocellular carcinoma; HCV, hepatitis C infection; MELD, model for end-stage liver disease; DRI, donor risk index; ICU, intensive care unit;
HBV, heptatitis B virus; ALD, alcohol-related liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosis
cholangitis.
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groups at 1 year: 89.4% for the HCC-/HCV- group, 87.2% for the
HCC+/HCV- and 89.5% for the HCC-/HCV+. There was a trend
in lower survival in patients with HCC+/HCV+ one cancer HCV
group (78.7%). At 5 years, the survival curves continue to diverge
(78.6%, 70.4%, 68.2% and 59.5%, respectively). The difference in
survival becomes striking at 10 years when the HCC+/HCV+
group has half the estimated survival (35.3%) when compared
with the control group (67.2%). The HCC control group and
HCV control group had survival rates of 57.1% and 57.5%,
respectively, similar to those of the control group. These results
translate into a median survival of the HCC+/HCV+ group
approaching one-third (6.7 years) of that of the HCC-/HCV-
group (>15.8 years). The HCC+/HCV- and HCC-/HCV+ have
median survivals of 12.3 and 11.8 years, respectively.
In the multivariate COX regression analysis for patient survival
(Table 4), after adjusting for age, MELD, gender and DRI, patients
with HCC+/HCV+ was the strongest predictor of death with a
hazard ratio (HR) of 1.91 (95% CI 1.24–2.95, P = 0.003). Having
HCV cirrhosis alone was also a negative predictor of survival with
a HR of 1.45 (95% CI, 0.99–2.12, P = 0.054) when compared with
the HCC-/HCV- group. The hazard of death in the HCC alone
group was comparable to that of controls (HR 1.18, 95% CI,









1 49 37.5% 50.8% 0.265
1 to 3 36 37.5% 25.4%
More than 3 28 25.0% 23.8%
Tumour grade
1 and 2 93 71.4% 84.1% 0.128
3 and 4 26 28.6% 15.9%
Microvascular invasion 34 37.5% 20.6% 0.042*
Total tumour size
Smaller than 5 cm 86 67.9% 76.2% 0.311
5 cm or more 33 32.1% 23.8%
Outside the Milan criteria 34 50.0% 20.6% 0.027*
Pre-operative treatment 39 39.6% 20.6% 0.283
HCC, hepatocellular carcinoma; HCV, hepatitis C infection.
*In six patients, not all tumour characteristics were available.
Chi-square or Fisher's exact tests were performed to compare the two groups.













Survival at 1 year 89.4% 87.2% 89.5% 78.7%
Survival at 5 years 78.6% 70.4% 68.2% 59.5%
Survival at 10 years 67.2% 57.1% 57.5% 35.3%
Survival at 15years 61.1% 46.1% 40.8% 18.8%
Median survival (years) >15.8 12.3 11.8 6.7
HCC, hepatocellular carcinoma; HCV, hepatitis C infection.
Figure 2 Kaplan–Meier survival curves and numbers at risk
Table 4 Results of the multivariate Cox regression analysis for
patient survival
Hazard ratio 95% CI P-value
HCC+ HCV- 1.18 0.71–1.93 0.508
HCC- HCV+ 1.45 0.99–2.12 0.054
HCC+ HCV+ 1.91 1.24–2.95 0.003*
Recipient age 1.04 1.02–1.06 <0.000*
Male 1.06 0.75–1.48 0.245
MELD score 1.01 0.99–1.03 0.716
DRI 1.68 1.11–2.56 0.015*
CI, confidence interval; HCC, hepatocellular carcinoma; HCV, hepatitis C
infection; MELD, model for end-stage liver disease; DRI, donor risk index.
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0.71–1.93, P = 0.508). Other than the cause of ESLD, DRI (HR
1.68, 95% CI, 1.11–2.56, P = 0.015) and recipient age (HR 1.04,
95% CI, 1.02–1.06, P < 0.000) were also independent predictors of
mortality. The MELD score was not found to be a significant
predictor of mortality.
After correcting for DRI, recipient age and MELD score, results
for graft survival (Table 5) were similar to those of patient sur-
vival. In summary, the HCC+/HCV+ had twice the hazard of
mortality when compared with the HCC+/HCV-. The HCV alone
group had the second highest risk of mortality with a HR of 1.61
(95% CI, 1.05–2.48, P = 0.028) whereas the HCC alone group had
a risk comparable to the controls. In this multivariate analysis,
DRI was a significant predictor of survival whereas recipient age
was not.
HCC survival
In spite of a clear advantage in tumour characteristics for the
HCC+/HCV+ group (Table 2), survival was twice as low in this
group when compared with the HCC+/HCV- group as can be
seen on the Kaplan–Meier curve (Fig. 2) and in the survival esti-
mates (Table 3). In this Cox sub-analysis, after correcting for
tumour characteristics and treatment, this trend persisted (HR
1.94, 95% CI, 1.06–3.81, P = 0.041) (Table 6). Total tumour size,
being outside Milan criteria, the presence of microvascular inva-
sion, recipient age and DRI did not have an impact on survival.
Cause of death (COD)
The COD as they occurred in the four groups are presented in
Table 7. There was a higher incidence of death owing to cardio-
vascular disease in the HCC+/HCV- group (P = 0.064) and a
higher incidence of COD owing to other causes (including acci-
dents) in the HCC+/HCV+ group (P = 0.038). The most common
COD by groups were malignancy in the HCC-/HCV- group
(8.3%), cardiovascular and respiratory in the HCC alone group
(15.8%) and HCV recurrence in the HCV alone group (23.6%).
The most common cause of COD in the HCC+/HCV+ study
group was also cirrhosis related to HCV recurrence, occurring in
17.9% of patients. HCC recurrence was low in this cohort of
patients as well as it was not the COD in the majority of HCC
patients in both HCV- and HCV+ patients.
Discussion
This study is the first in the literature to assess the long-term
impact of HCV on post-LT survival in patients with HCC. It was
shown that the coexistence of HCC and HCV has the most del-
eterious impact on long-term patient and graft survival, doubling
the risk of mortality. These results persist even after correcting for
all other covariates.
Two previous studies have found results that differ from the
present.16,17 A study of the United Network for Organ Sharing
(UNOS) database comparing changes in survival in patients with
HCC and HCV found no independent impact on survival in HCV
and HCC patients.17 In spite of being the largest described cohort,
the survival assessment in that study was limited at 5 years. At the
5-year point, this study describes similar results, suggesting that
the impact of HCV might not be that important in the short term.
However, it was demonstrated that HCV bears a significant toll on
long-term survival (10 years). Furthermore, although the Thulu-
vath et al. study accounted for numerous peri-operative variables,
the authors did not correct for tumour characteristics, did not
report COD and had limited ascertainment of mortality.
A single-centre study by Doyle et al. concluded that in the
MELD era, there was no significant difference in survival between
patients with hepatitis C and HCC and patients with HCC alone
on Kaplan–Meier analysis.16 However, this study also did not
adjust for tumour characteristics and other variables that are
known to be independent predictors of survival.20 In this study, it
was found that in spite of having more advanced tumour charac-
teristics, the HCC+/HCV- group had a better survival on Kaplan–
Meier analysis. In this multivariate sub-analysis of survival in all
HCC+ patients, HCV remained an independent predictor of sur-
vival, increasing the mortality risk by almost two-fold.
Four studies have reported results supporting our
conclusions.11–13,15 However, these studies only have a 5-year sur-
Table 5 Results of the multivariate Cox regression analysis for graft
survival
Hazard ratio 95% CI P-value
HCC+ HCV- 1.13 0.61–2.08 0.744
HCC- HCV+ 1.61 1.05–2.48 0.028*
HCC+ HCV+ 1.86 1.14–3.08 0.014*
Recipient age 1.02 1.00–1.03 0.093
Male 1.15 0.75–1.49 0.512
MELD score 1.00 0.98–1.03 0.716
DRI 1.73 1.06–2.82 0.028*
CI, confidence interval; HCC, hepatocellular carcinoma; HCV, hepatitis C
infection; MELD, model for end-stage liver disease; DRI, donor risk index.
Table 6 Results of the multivariate Cox regression, a sub-analysis of
all patients with hepatocellular carcinoma (HCC)
Hazard ratio 95% CI P-value
HCC+ HCV- Baseline risk
HCC+ HCV+ 1.94 1.06–3.81 0.041*
Recipient age 1.03 0.99–1.03 0.171
Male 0.89 0.46–2.63 0.793
MELD score 1.04 0.92–1.15 0.613
DRI 1.35 0.66–2.93 0.446
Micro-vascular invasion 1.52 0.88–3.93 0.103
Treatment 1.35 0.72–2.53 0.353
Outside Milan criteria 1.22 0.60–2.45 0.200
HCV, hepatitis C infection; MELD, model for end-stage liver disease;
DRI, donor risk index.
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vival analysis. Moreover, only one study performed a multivariate
analysis for overall survival. The Moya et al. study found that
viral-related aetiology of cirrhosis, tumour recurrence and older
donor age remained the only independent predictors of survival
after correcting for other variables.14,15
In the present multivariate Cox regression, the DRI emerged as
an independent predictor of survival. The DRI, established in
2006 by Feng et al.,19 is a proven and validated negative predictor
of survival.21,22 This cohort is a homogenous Caucasian popula-
tion, living in proximity to the transplanting centre, in which the
use of deceased-after-cardiac-death donors is very limited and few
split-liver transplants are performed. Therefore, the main varia-
tions in the DRI are attributed to donor age. This is in agreement
with previous studies that have shown that donor age is a signifi-
cant independent predictor of poor survival14,15,17 and even more
so in HCV+ patients.23,24 Moreover, a study of the UNOS database
found a synergistic interaction between DRI and recipient HCV
status;25 patients with a high DRI were reported to have a worse
survival in HCV+ recipients than in HCV- recipients.
In the same analysis, recipient age was also an independent
predictor of survival. This finding is in accordance with older and
more recent UNOS studies,17,26 as well as with the United Kingdom
(UK) transplant database results.27 We found that patients with
HCC tend to be, on average, 5 years older than their non-HCC
counterparts, independent of HCV status. This is probably second-
ary to the fact that the lead-time for HCC recurrence after liver
cirrhosis is longer than the development of cirrhosis itself.
Another important result is that the major COD in all HCV+
patients, whether HCC- or HCC+ (23.6% and 17.9% respec-
tively), was HCV recurrence. Doyle et al. found that HCC+/HCV+
recipients in their cohort did not die from recurrent HCV
(3.9%).16 However, Moya et al. found similar results with their
COD in all HCC patients being HCV-related graft cirrhosis
(8%).15 Shimoda et al. also found HCV recurrence to be the
second COD in HCC+/HCV+ recipients, whereas HCC recur-
rence was the third most common COD,18 supporting the present
results. A study on the pattern of late mortality post-LT in the UK
found that graft failure (including HCV recurrence) was the main
COD at 10 years (20%) in all LT patients.27 Their second most
prevalent cause of mortality was cardiac (12%), similar to our
HCC+/HCV- recipients (15.8%).
To summarize, in this cohort, a high DRI (mainly older donor
age) and an older recipient age, together with HCV, interacted to
yield a lower overall survival for HCC+/HCV+ patients. It is rec-
ognized that almost all HCV+ patients receiving a liver allograft
tend to recur.28,29 Donor age is a significant predictor of graft
quality and may increase the impact of HCV recurrence on graft
survival.27 This explains why the main COD in all HCV+ patients
in our cohort is HCV recurrence. It is possible that HCV recur-
rence may have less of a detrimental effect in younger donor livers.
Given that our donor pool is significantly older than other centres,
this risk factor might not be modifiable but a better optimization
in donor selection should be the aim. The main remediable risk
factor remains HCV recurrence. Although there has been an
improvement in treatment strategies and immunosuppression,
the benefits of these new strategies remain contentious.30–33
In the present cohort, tumour characteristics were not found to
be significant predictors of long-term survival. This is probably as
a result of the fact that the HCC recurrence rate was low (18.4%),
possibly creating a small number of effects. Moreover, HCC alone
had no increased risk of death when compared with the HCC-/
HCV- patients. It is interesting to note that many of the HCC+/
HCV- patients were HBV positive (42.1%, Table 1). The
comparable survival is probably as a result of the fact that trans-
plantation is curative in HBV-positive recipients and graft
re-infection is now a rarity since the introduction of hepatitis B
immune globulin and nucleoside analogue prophylaxis.25,34
It is noteworthy that the underlying cause of ESLD in HCC
differs between regions.4,35 While HCV is the leading cause of
cirrhosis in Europe, North America and Japan, HBV is the main
Table 7 Causes of death by hepatocellular carcinoma/hepatitis C infection (HCC/HCV) group (A chi-squared or Fisher's analysis was
performed to compare the prevalence)













Cardiovascular and respiratory 7.5% 15.8% 3.8% 6.0% 0.064
Sepsis 4.7% 5.3% 3.8% 1.5% 0.665
Biliary sepsis 1.2% 0% 2.9% 1.5% 0.739
Renal 1.2% 0% 0% 0% 0.819
Malignancy 8.3% 7.0% 5.7% 1.5% 0.223
Transplant related complications 2.0% 1.8% 2.8% 1.5% 0.958
Other causes 3.2% 0% 0% 6.0% 0.038*
HCV recurrence 0% 0% 23.6% 17.9% 0.245
HCC recurrence 0% 7.0% 0% 10.5% 0.365
Total 27.8% 37.9% 40.6% 46.3%
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cause of ESLD in Africa and Asia.36 In our cohort, HCV is the first
cause of ESLD at 36.3%, three times more than HBV (12.6%). The
HCV+ population transplanted at this centre is different from
many other centres, as it is constituted of immigrants infected in
Southern and Eastern Europe and the Middle East. This renders
the present population somewhat unique and may limit the exter-
nal validity of our results.
The limitations of this study are those inherent to a retrospec-
tive study although data collection was prospective and performed
in a systematic and standardized fashion. The advantage of using
our institutional database when compared with national data-
bases is that this cohort has near complete follow-up (98.8%).
This enables a long follow-up (up to 19 years in some cases) and
a very accurate outcome ascertainment, shedding light on the
long-term causes of mortality.
Results are less prone to misclassification and recall bias error;
however, a random misclassification error can still be present.
There is little selection bias introduced in this study as all LT
performed at our centre were considered and only patients that
died or underwent a redo within the first 30 days were excluded.
While no sensitivity analysis was performed, the 90-day compli-
cation causes and rates were equally distributed among the
groups. The rationale behind this exclusion was to focus on long-
term survival and not be influenced by what are probably techni-
cal errors. Only first grafts in the graft survival analysis were
included; however, survival of subsequent grafts was indirectly
included in the overall patient survival. Given that the patient and
graft survival analysis yield very similar results, a selection bias
introduced by this exclusion criterion is highly unlikely.
Conclusion
This study is the first to assess the long-term impact of HCV on
post-LT survival in HCC patients. Patients with HCV have a sig-
nificantly lower survival after LT when compared with HCV nega-
tive patients. HCC alone has almost no impact on patient survival
in our cohort. Patient survival is dramatically decreased when
HCC and HVC are both present. Nevertheless, the attributable
impact of HCV is greater than that of HCC. Controlling HCV
recurrence and other modifiable variables such as donor age and
DRI, especially in HCV positive patients, could greatly improve
the long-term survival.
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